Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Skin Cancer01:30

Skin Cancer

3.1K
Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
3.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.4K
Tumor Immunotherapy01:27

Tumor Immunotherapy

475
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
475

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma: Part 2. Treatment - update 2026.

European journal of cancer (Oxford, England : 1990)·2026
Same author

European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma. Part 1: Diagnostics and prevention - Update 2026.

European journal of cancer (Oxford, England : 1990)·2026
Same author

Perspectives on Artificial Intelligence in Dermatology: An International Cross-Sectional Study.

Medicina (Kaunas, Lithuania)·2026
Same author

A Risk-Scoring Classifier for the Diagnosis and Management of Atypical Melanocytic Lesions of the Palms: the iDScore_palmar Model.

Dermatology practical & conceptual·2026
Same author

Clinical, Dermatoscopic, Histological and Molecular Prognostic and Predictive Factors of Metastatic Melanoma Response to Immunotherapy: A Systematic Review and Drug Class Meta-Analysis.

Journal of clinical medicine·2026
Same author

Comparative and complementary diagnostic value of dermatoscopy and clinical close-up photography in skin cancer diagnosis: A study from the MILK10k dataset.

Journal of the American Academy of Dermatology·2026

Related Experiment Video

Updated: Jun 4, 2025

Author Spotlight: Non-Surgical Treatment of Melasma– Microneedling with Tranexamic Acid
04:12

Author Spotlight: Non-Surgical Treatment of Melasma– Microneedling with Tranexamic Acid

Published on: January 19, 2024

798

European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2024.

Claus Garbe1, Teresa Amaral1, Ketty Peris2

  • 1Center for Dermatooncology, Department of Dermatology, Eberhard Karls University, Tuebingen, Germany.

European Journal of Cancer (Oxford, England : 1990)
|December 22, 2024
PubMed
Summary

This guideline provides updated recommendations for cutaneous melanoma diagnosis and treatment, emphasizing interdisciplinary tumor boards and tailored adjuvant/neoadjuvant therapies including immunotherapy and targeted agents. It covers stages II-IV, recurrence, and unresectable disease, valid until 2026.

Keywords:
Adjuvant therapyBRAF and MEK inhibitorsBrain metastasesCutaneous melanomaImmune checkpoint inhibitorsNeoadjuvant therapyTargeted therapy

More Related Videos

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis
07:41

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis

Published on: March 8, 2022

2.4K
Isolated Hepatic Perfusion as a Treatment for Liver Metastases of Uveal Melanoma
09:52

Isolated Hepatic Perfusion as a Treatment for Liver Metastases of Uveal Melanoma

Published on: January 25, 2015

13.4K

Related Experiment Videos

Last Updated: Jun 4, 2025

Author Spotlight: Non-Surgical Treatment of Melasma– Microneedling with Tranexamic Acid
04:12

Author Spotlight: Non-Surgical Treatment of Melasma– Microneedling with Tranexamic Acid

Published on: January 19, 2024

798
A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis
07:41

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis

Published on: March 8, 2022

2.4K
Isolated Hepatic Perfusion as a Treatment for Liver Metastases of Uveal Melanoma
09:52

Isolated Hepatic Perfusion as a Treatment for Liver Metastases of Uveal Melanoma

Published on: January 25, 2015

13.4K

Area of Science:

  • Dermato-Oncology
  • Medical Oncology
  • Clinical Guidelines

Background:

  • Cutaneous melanoma diagnosis and treatment require updated, evidence-based recommendations.
  • Multidisciplinary expert collaboration is crucial for optimal patient management.

Purpose of the Study:

  • To provide evidence-based recommendations for cutaneous melanoma diagnosis and treatment.
  • To guide therapeutic decisions for various stages of melanoma, including adjuvant, neoadjuvant, and systemic therapies.

Main Methods:

  • Systematic literature reviews.
  • Consensus from multi-disciplinary experts from EADO, EDF, and EORTC.
  • Development of clinical guidelines for melanoma management.

Main Results:

  • Recommendations for sentinel lymph node biopsy in specific melanoma cases.
  • Guidance on adjuvant therapies (PD-1 inhibitors, BRAF/MEK inhibitors) for resected stages IIB-IV.
  • Strategies for neoadjuvant therapy and treatment of unresectable or recurrent disease, including immunotherapy combinations.

Conclusions:

  • Interdisciplinary tumor board decisions are paramount for melanoma treatment.
  • Tailored adjuvant and neoadjuvant therapies, including immunotherapy and targeted agents, improve outcomes.
  • Updated guidelines address complex scenarios like recurrence and unresectable disease, valid until 2026.